Search research articles
Contact Us
Filters
Showing results (251-260 of 294) with videos related to
Page
of 30
Sort By:
JAMA
|
May 26, 2018
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial
Edward M Messing, Catherine M Tangen, Seth P Lerner, et al.
BJU International
|
February 6, 2010
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
Shahrokh F Shariat, Robert S Svatek, Derya Tilki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2010
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder
Robert S Svatek, Shahrokh F Shariat, Robert E Lasky, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Jens-Peter Volkmer, Debashis Sahoo, Robert K Chin, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
Anita L Sabichi, Seth P Lerner, E Neely Atkinson, et al.
European Urology Oncology
|
October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Roger Li, Patrick J Hensley, Marko Babjuk, et al.
Cancer & Metabolism
|
April 2, 2026
Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer
Abu Hena Mostafa Kamal, Vasanta Putluri, Tanmay Gandhi, et al.
European Urology
|
May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer
Marie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 294) with videos related to
Sort By:
Page
of 30
JAMA
|
May 26, 2018
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial
Edward M Messing, Catherine M Tangen, Seth P Lerner, et al.
BJU International
|
February 6, 2010
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
Shahrokh F Shariat, Robert S Svatek, Derya Tilki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2010
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder
Robert S Svatek, Shahrokh F Shariat, Robert E Lasky, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Jens-Peter Volkmer, Debashis Sahoo, Robert K Chin, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
Anita L Sabichi, Seth P Lerner, E Neely Atkinson, et al.
European Urology Oncology
|
October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Roger Li, Patrick J Hensley, Marko Babjuk, et al.
Cancer & Metabolism
|
April 2, 2026
Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer
Abu Hena Mostafa Kamal, Vasanta Putluri, Tanmay Gandhi, et al.
European Urology
|
May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer
Marie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Page
of 30